L. Parker Gregg (@lparkergregg1) 's Twitter Profile
L. Parker Gregg

@lparkergregg1

Nephrologist, researcher in fatigue and depression in people with #KidneyDisease, educator, #NSMC grad. Tweets are my own and are not medical advice.

ID: 1056752913903767552

calendar_today29-10-2018 03:41:43

1,1K Tweet

1,1K Takipçi

632 Takip Edilen

Andreas Kronbichler (@akronbichler) 's Twitter Profile Photo

The Covid-19 pandemic had a major impact on patient care. JASN_News and others were guiding us through the pandemic. Please find a take on what was relevant to us throughout the pandemic. A perspective looking back at difficult times; L. Parker Gregg Joanne Bargman

The Covid-19 pandemic had a major impact on patient care. <a href="/JASN_News/">JASN_News</a> and others were guiding us through the pandemic. Please find a take on what was relevant to us throughout the pandemic. A perspective looking back at difficult times; <a href="/LParkerGregg1/">L. Parker Gregg</a> <a href="/JoanneBargman/">Joanne Bargman</a>
L. Parker Gregg (@lparkergregg1) 's Twitter Profile Photo

Was an honor and a ton of fun to be on this podcast! Dr. Perchinsky’s insights from his experience as a patient are so valuable and worth listening to for anyone who knows or cares for people living with kidney disease. Excited to keep working to improve this issue for patients!

Paul Pharoah (R soul) 🇪🇺🇵🇬🇿🇦🇬🇧 (@paulpharoah) 's Twitter Profile Photo

1. This thread is my guide to preparing for a talk. The starting point is a story told by Niels Bohr during a lecture on complementarity theory. Once upon a time a young student went to hear three lectures by a famous rabbi. Afterwards he told his friends:

Andreas Kronbichler (@akronbichler) 's Twitter Profile Photo

Don’t feel fatigued when watching this! A huge unmet need in nephrology! Thanks to L. Parker Gregg and others, research will hopefully help us to improve it!

L. Parker Gregg (@lparkergregg1) 's Twitter Profile Photo

Was an honor to get to be part of this! I’m thrilled interest in fatigue is increasing among the nephrology community. We have work to do to improve patients’ lives and better understand this serious problem.

ASN Kidney News (@kidneynews) 's Twitter Profile Photo

Patients living with the spectrum of kidney diseases have high rates of mental illnesses. In honor of National Mental Health Awareness Month, this special issue of Kidney News is dedicated to shining a light on some of these important concerns bit.ly/3yN0seX

Patients living with the spectrum of kidney diseases have high rates of mental illnesses. In honor of National Mental Health Awareness Month, this special issue of Kidney News is dedicated to shining a light on some of these important concerns bit.ly/3yN0seX
ASN Kidney News (@kidneynews) 's Twitter Profile Photo

Living with kidney diseases can profoundly affect mental health and well-being. Austin Lee and Jackson Goodrich, two individuals living with kidney diseases, share their personal experiences of managing their mental health alongside their kidney health bit.ly/3yQhby8

Living with kidney diseases can profoundly affect mental health and well-being. Austin Lee and Jackson Goodrich, two individuals living with kidney diseases, share their personal experiences of managing their mental health alongside their kidney health bit.ly/3yQhby8
ASN Kidney News (@kidneynews) 's Twitter Profile Photo

In the past decades, medical technologies have transformed our relationship with death and dying. How have these advancements affected existential challenges at the end of life for people receiving dialysis? bit.ly/3VvS2le

In the past decades, medical technologies have transformed our relationship with death and dying. How have these advancements affected existential challenges at the end of life for people receiving dialysis? bit.ly/3VvS2le
JASN_News (@jasn_news) 's Twitter Profile Photo

SGLT2 inhibitors and GLP1-RA slow the worsening of kidney disease and improve cardiovascular outcomes in patients with CKD. A study shows that among patients with CKD, these agents are frequently discontinued, and discontinuation is associated with hospitalization, race,

SGLT2 inhibitors and GLP1-RA slow the worsening of kidney disease and improve cardiovascular outcomes in patients with CKD. A study shows that among patients with CKD, these agents are frequently discontinued, and discontinuation is associated with hospitalization, race,